Related Experiment Video

Updated: May 10, 2026

A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition
04:53

A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition

Published on: September 20, 2019

Statins in heart failure: do we need another trial?

Kwadwo Osei Bonsu1, Amudha Kadirvelu, Daniel Diamond Reidpath

  • 1School of Medicine and Health Sciences, Monash University Sunway Campus, Bandar Sunway, Malaysia.

Vascular Health and Risk Management
|June 29, 2013
PubMed

Insights

Statins, used for cardiovascular disease prevention, show conflicting evidence regarding benefits in heart failure. This review examines their role in heart failure pathophysiology and current research supporting their use.

Area of Science:

  • Cardiology
  • Pharmacology
  • Heart Failure Research

Background:

  • Statins are widely used to lower cholesterol and prevent cardiovascular events.
  • Previous evidence suggested statins benefit heart failure patients, but recent trials show mixed results.
  • Statins possess pleiotropic effects beyond cholesterol-lowering that may impact heart failure.

Purpose of the Study:

  • To review the role of statins in heart failure pathophysiology.
  • To analyze current evidence for statin efficacy in heart failure.
  • To identify future research directions in this field.

Main Methods:

  • Review of observational studies, retrospective data, and post hoc analyses.
  • Inclusion of data from large statin trials and smaller randomized trials.
  • Synthesis of recent studies and clinical evidence.

Main Results:

  • Conflicting evidence exists regarding statin benefits in heart failure.
  • Observational data and smaller trials suggest positive outcomes.
  • Recent large trials present contradictory findings, necessitating further investigation.

Conclusions:

  • The role of statins in heart failure remains debated.
  • Pleiotropic effects warrant continued exploration in heart failure management.
  • Further research is crucial to clarify statin's place in heart failure therapy.

Keywords:
comorbidityheart failuremortalitystatinstreatment

Related Concept Videos

Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...